Plain-English translation of NCT07194980 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a daily oral medication, combined with (a type of cell therapy) for patients whose chronic lymphocytic leukemia or small lymphocytic lymphoma has come back or stopped responding to standard treatments. The study is checking whether adding this medication to the cell therapy is safe and whether it helps patients live longer without their cancer returning. About 20 patients will participate.
Chronic lymphocytic leukemia can be very difficult to treat once it returns or becomes resistant to standard therapies. This medication is being studied because researchers believe it may work together with cell therapy to better control the disease and improve outcomes for patients with limited options.
You likely qualify if…
You likely don't qualify if…
You would take the daily oral medication for up to one year while receiving the cell therapy as part of your treatment plan. Before the main therapy starts, you'll have a procedure called leukapheresis to collect your blood cells, followed by standard chemotherapy to prepare your body. Then you'll receive the cell therapy infusion. Throughout the study, you'll have regular blood tests, imaging scans (like PET/CT scans), heart imaging, and bone marrow samples taken to monitor how well the treatment is working and check for side effects. After treatment ends, you'll continue being followed for 5 years.
AI-generated summary from trial data · Jul 22, 2026 · Not medical advice
United States